ESCRS 2023: Presbyopia treatment with microporation therapeutic technology by Ace Vision Group
AnnMarie Hipsley, DPT, PhD, Founder and CEO of Ace Vision Group, met with Ophthalmology Times Europe at the 2023 European Society of Cataract and Refractive Surgeons to discuss Ace Vision Group’s microporation therapeutic technology, used to treat presbyopia.
Explore More Articles
Pathogenesis of Presbyopia: A New Understanding of an Age-Old Disease
FOR MOST OF HISTORY, PRESBYOPIA has been defined as a “normal” refractive error caused by age, with discussion limited to the loss of near vision beginning in our 40s. Because we have had no effective therapeutic interventions available, presbyopia has been accepted as a natural part of life and treated primarily by changing power at either …
read moreAce Vision Group Strengthens Executive Team with Addition of Frank Chen as Chief Operating Officer
Ace Vision Group, Inc., an emerging medical device company at the forefront of pioneering a laser microporation therapy for the aging eye, today announced the appointment of Frank Chen as Chief Operating Officer (COO). Mr. Chen brings extensive management to enhance operational efficiencies and drive business growth at Ace Vision Group (AVG).
read moreLaser scleral microporation has high satisfaction in emmetropic presbyopes
SAN DIEGO — In this Healio Video Perspective from the ASCRS meeting, Robert Ang, MD, discusses 18-month study outcomes of laser scleral microporation in emmetropic presbyopes. “Our studies show that the patients have high patient satisfaction with laser scleral microporation treatment,” he said. “It is safe and effective, and it has great potential for this segment of …
read more